Get the Stockscreener App
1.535
1.66%
0.025
Cerus Corp stock is traded at $1.535, with a volume of 617.68K.
It is up +1.66% in the last 24 hours and down -5.83% over the past month.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
See More
Previous Close:
$1.51
Open:
$1.54
24h Volume:
617.68K
Relative Volume:
0.47
Market Cap:
$293.30M
Revenue:
$156.37M
Net Income/Loss:
$-37.49M
P/E Ratio:
-7.3095
EPS:
-0.21
Net Cash Flow:
$-47.77M
1W Performance:
-4.06%
1M Performance:
-5.83%
6M Performance:
+14.55%
1Y Performance:
-7.53%
1-Day Range:
$1.49
$1.59
1-Week Range:
$1.48
$1.6489
52-Week Range:
$1.12
$2.235
Cerus Corp Stock (CERS) Company Profile
Name
Cerus Corp
Sector
Industry
Phone
(925) 288-6000
Address
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERS
Cerus Corp
|
1.53 | 290.05M | 156.37M | -37.49M | -47.77M | -0.21 |
|
ABT
Abbott Laboratories
|
124.37 | 219.36B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.94 | 143.81B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
362.58 | 139.29B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.40 | 128.70B | 34.76B | 4.79B | 5.30B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
84.86 | 49.92B | 5.88B | 1.34B | 799.60M | 2.3489 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-24 | Initiated | Craig Hallum | Buy |
| Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-26-20 | Initiated | BTIG Research | Buy |
| Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
| Aug-28-19 | Initiated | Stifel | Buy |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-08-17 | Resumed | BTIG Research | Neutral |
| Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
| Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
| May-02-14 | Reiterated | MLV & Co | Buy |
| Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-15-13 | Reiterated | MLV & Co | Buy |
| Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
| Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-10-11 | Reiterated | MLV & Co | Buy |
| Jun-03-11 | Initiated | Wedbush | Outperform |
| Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp Stock (CERS) Latest News
Is Cerus Corporation stock resilient to inflation2025 Bull vs Bear & Momentum Based Trading Signals - newser.com
Will Cerus Corporation (CU2) stock outperform global peersWeekly Investment Recap & Technical Pattern Based Signals - newser.com
Why Cerus Corporation (CU2) stock stays resilientInsider Buying & Weekly Watchlist for Consistent Profits - newser.com
How sustainable is Cerus Corporation stock dividend payoutTrade Volume Report & Weekly Setup with ROI Potential - newser.com
Why Cerus Corporation (CU2) stock appears on watchlistsJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
What makes Cerus Corporation (CU2) stock appealing to growth investorsQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - newser.com
Is Cerus Corporation (CU2) stock safe for risk averse investors2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
How Cerus Corporation (CU2) stock performs in volatility spikes2025 Trading Recap & AI Forecast for Swing Trade Picks - newser.com
How Cerus Corporation stock benefits from strong dollarMarket Growth Review & Free AI Powered Buy and Sell Recommendations - newser.com
Is Cerus Corporation stock a good choice for value investorsGap Up & Breakout Confirmation Trade Signals - newser.com
Relative strength of Cerus Corporation in sector analysisPortfolio Risk Summary & Growth Focused Stock Reports - newser.com
How Cerus Corporation stock reacts to bond yieldsJuly 2025 Technicals & Real-Time Stock Movement Alerts - newser.com
Can Cerus Corporation stock hit record highs again2025 Technical Overview & Advanced Technical Analysis Signals - newser.com
Will Cerus Corporation stock reach Wall Street targetsJuly 2025 Technicals & Verified Swing Trading Watchlists - newser.com
How Cerus Corporation (CU2) stock responds to job market shiftsPortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Is Cerus Corporation stock positioned well for digital economy2025 Key Highlights & Daily Profit Maximizing Trade Tips - newser.com
Senvest Management LLC Has $5.65 Million Stock Position in Cerus Corporation $CERS - MarketBeat
Can Cerus Corporation stock hit analyst price targets2025 Market Trends & Fast Entry High Yield Stock Tips - newser.com
Why Cerus Corporation (CU2) stock attracts wealthy investorsRecession Risk & Smart Swing Trading Techniques - newser.com
Cerus Corp Stock (CERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cerus Corp Stock (CERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jensen Chrystal | Chief Legal Officer |
Mar 14 '25 |
Sale |
1.45 |
30,075 |
43,609 |
783,294 |
| Jensen Chrystal | Chief Legal Officer |
Mar 13 '25 |
Sale |
1.45 |
18,949 |
27,476 |
813,369 |
| Jayaraman Vivek K | Chief Operating Officer |
Mar 14 '25 |
Sale |
1.45 |
46,004 |
66,706 |
1,431,326 |
| Jayaraman Vivek K | Chief Operating Officer |
Mar 13 '25 |
Sale |
1.45 |
29,985 |
43,478 |
1,477,330 |
| Greenman William Mariner | President and CEO |
Mar 14 '25 |
Sale |
1.45 |
122,827 |
178,099 |
4,115,845 |
| Greenman William Mariner | President and CEO |
Mar 13 '25 |
Sale |
1.45 |
71,086 |
103,075 |
4,238,672 |
| Green Kevin Dennis | Chief Financial Officer |
Mar 14 '25 |
Sale |
1.45 |
36,740 |
53,273 |
875,867 |
| Green Kevin Dennis | Chief Financial Officer |
Mar 13 '25 |
Sale |
1.45 |
23,147 |
33,563 |
912,607 |
| Benjamin Richard J | Chief Medical Officer |
Mar 14 '25 |
Sale |
1.45 |
30,075 |
43,609 |
685,775 |
| Benjamin Richard J | Chief Medical Officer |
Mar 13 '25 |
Sale |
1.45 |
18,949 |
27,476 |
715,850 |
6.67%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):